Lotte Biologics Co. Ltd. said it partnered with domestic bioventure Kanaph Therapeutics Inc. to develop an antibody-drug conjugate (ADC) technology platform in hopes of rounding out a full, in-house ADC value-chain.

Kelun-Biotech Biopharmaceutical Co. Ltd. raised HK$1.36 billion (US$174 million) in an IPO in Hong Kong to support its push into the increasingly competitive antibody-drug conjugate (ADC) market in China.

Extending its efforts in the booming antibody-drug conjugate (ADC) space, Beigene Co. Ltd. tapped Duality Biologics Co. Ltd. in a deal that could be worth a potential $1.3 billion, picking up an option for rights to a preclinical-stage ADC candidate targeting select solid tumors. It marks the seventh $1 billion-plus ADC-focused deal so far in 2023 and the second for Dualitybio, which inked a potential $1.7 billion deal in April.

Beigene Co. Ltd. and Duality Biologics (Suzhou) Co. Ltd. have signed an agreement for Beigene to acquire an exclusive option for a global clinical and commercial license to a preclinical antibody-drug conjugate (ADC) therapy for select solid tumors.

Extending its efforts in the booming antibody-drug conjugate (ADC) space, Beigene Co. Ltd. tapped Duality Biologics Co. Ltd. in a deal that could be worth a potential $1.3 billion, picking up an option for rights to a preclinical-stage ADC candidate targeting select solid tumors. It marks the seventh $1 billion-plus ADC-focused deal so far in 2023 and the second for Dualitybio, which inked a potential $1.7 billion deal in April.

Lantern Pharma Inc. has entered into a research collaboration with Bielefeld University to develop antibody-drug conjugates (ADCs) with therapeutic and antitumor potential. Using Lantern’s proprietary artificial intelligence (AI) platform, RADR, the collaboration will leverage insights from the recently developed RADR AI ADC module in combination with research from Bielefeld.

Nectin cell adhesion molecule 4 (Nectin-4) overexpression in different tumors correlates with cancer progression and poor prognosis in many human malignancies. The first Nectin-4-targeting antibody, enfortumab vedotin (EV), has limited efficacy and frequent adverse effects in several solid tumors. Researchers at Mabwell (Shanghai) Bioscience Co. Ltd. and colleagues have now reported on the generation and characterization of 9MW-2821, an antibody-drug conjugate consisting of an antibody targeting Nectin-4 conjugated to monomethyl auristatin E (MMAE).